Who are EV71vac's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Healive+Havrix, Hepatitis A Virus, IXIARO®- Japanese Encephalitis vaccine, Havrix+Havrix, Havrix+Healive, Comparator: VAQTA™.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ev71vac.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

EV71vac — Competitive Intelligence Brief

EV71vac (EV71vac) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated viral vaccine. Area: Immunology / Infectious Disease.

phase 3 Inactivated viral vaccine Enterovirus 71 (EV71) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

EV71vac (EV71vac) — Medigen Vaccine Biologics Corp.. EV71vac is an inactivated vaccine that stimulates the immune system to produce antibodies and cellular immunity against Enterovirus 71 (EV71).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
EV71vac TARGET	EV71vac	Medigen Vaccine Biologics Corp.	phase 3	Inactivated viral vaccine	Enterovirus 71 (EV71)
Healive+Havrix	Healive+Havrix	Sinovac Biotech Co., Ltd	marketed	Inactivated viral vaccine combination
Hepatitis A Virus	Hepatitis A Virus	Novartis	marketed	Inactivated viral vaccine	Hepatitis A Virus surface antigens
IXIARO®- Japanese Encephalitis vaccine	IXIARO®- Japanese Encephalitis vaccine	Medical University of Vienna	marketed	Inactivated viral vaccine
Havrix+Havrix	Havrix+Havrix	Sinovac Biotech Co., Ltd	marketed	Inactivated viral vaccine	Hepatitis A virus (HAV)
Havrix+Healive	Havrix+Healive	Sinovac Biotech Co., Ltd	marketed	Combination inactivated viral vaccine	Hepatitis A virus antigen; Hepatitis B surface antigen (HBsAg)
Comparator: VAQTA™	Comparator: VAQTA™	Merck Sharp & Dohme LLC	marketed	Inactivated viral vaccine	Hepatitis A virus antigen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated viral vaccine class)

Sinovac Biotech Co., Ltd · 9 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
GlaxoSmithKline · 5 drugs in this class
Valneva Austria GmbH · 4 drugs in this class
Medical University of Vienna · 3 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
China National Biotec Group Company Limited · 2 drugs in this class
Statens Serum Institut · 2 drugs in this class
Institute of Medical Biology, Chinese Academy of Medical Sciences · 2 drugs in this class
Crucell Holland BV · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EV71vac — Competitive Intelligence Brief. https://druglandscape.com/ci/ev71vac. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab